PALX

SEC source: 0001493152-26-035982 · ownership.xml · nonDerivative · entry 1

Ogawa Richard · CIK 0001568078 · Director · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,882,500

F1 · kind: Pursuant to the terms of a certain Share Exchange Agreement and Plan of Reorganization, dated as of July 31, 2026, by and among Palomino Laboratories Inc. (the "Purchaser"), Vega Links, Inc. ("VLI") and the stockholders as listed on Schedule A attached thereto (the "Stockholders"), the Stockholders, who directly owned one hundred percent (100%) of the shares of VLI (the "Shares"), sold all the Shares to the Purchaser in exchange for 4,472,000 shares of the common stock, par value $0.0001 per share of the Purchaser ("Purchaser Stock"). As part of this transaction, Richard Ogawa, as a shareholder of VLI, received 120,000 shares of Purchaser Stock in exchange for his 300,000 shares of VLI.

SEC source: 0001493152-26-018119 · ownership.xml · nonDerivative · entry 1

Ogawa Richard · CIK 0001568078 · Director · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,762,500

SEC source: 0001493152-26-018116 · ownership.xml · nonDerivative · entry 1

Denbaars Steven · CIK 0001700533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,762,500

SEC source: 0001213900-25-095630 · ownership.xml · nonDerivative · entry 1

Lucius Partners LLC · CIK 0002002106 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000,000

F1 · kind: Pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of September 29, 2025, and pursuant to the terms of a stock cancellation agreement, the reporting person voluntarily surrendered and cancelled for no consideration 1,000,000 shares of Issuer's common stock in connection with the consummation of the Merger on September 29, 2025. Matthew Eitner has the power to vote and to dispose of the shares held by Lucius Partners LLC and may be deemed the beneficial owner of the shares.

F1 · price: Pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of September 29, 2025, and pursuant to the terms of a stock cancellation agreement, the reporting person voluntarily surrendered and cancelled for no consideration 1,000,000 shares of Issuer's common stock in connection with the consummation of the Merger on September 29, 2025. Matthew Eitner has the power to vote and to dispose of the shares held by Lucius Partners LLC and may be deemed the beneficial owner of the shares.

F1 · ownership.direct: Pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated as of September 29, 2025, and pursuant to the terms of a stock cancellation agreement, the reporting person voluntarily surrendered and cancelled for no consideration 1,000,000 shares of Issuer's common stock in connection with the consummation of the Merger on September 29, 2025. Matthew Eitner has the power to vote and to dispose of the shares held by Lucius Partners LLC and may be deemed the beneficial owner of the shares.

SEC source: 0001493152-25-017568 · ownership.xml · derivative · entry 2

Tu Jason · CIK 0002089678 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,667

Underlying: Common Stock · 41,667 shares

Expires not disclosed

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · derivative.expiration_date: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

SEC source: 0001493152-25-017568 · ownership.xml · nonDerivative · entry 1

Tu Jason · CIK 0002089678 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,001

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · price: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Tu, as a shareholder of Pre-Merger Palomino, received 41,667 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Tu converted his SAFEs into 41,667 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

SEC source: 0001493152-25-017607 · ownership.xml · derivative · entry 2

Denbaars Steven · CIK 0001700533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires not disclosed

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

F1 · derivative.expiration_date: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

SEC source: 0001493152-25-017607 · ownership.xml · nonDerivative · entry 1

Denbaars Steven · CIK 0001700533 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,750,000

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

F1 · price: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. DenBaars, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, during which, Mr. DenBaars converted his SAFEs into 125,000 Units at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in warrant agreement).

SEC source: 0001493152-25-017571 · ownership.xml · derivative · entry 2

Ogawa Richard · CIK 0001568078 · Director · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires not disclosed

F1 · kind: Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · derivative.expiration_date: Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

SEC source: 0001493152-25-017571 · ownership.xml · nonDerivative · entry 1

Ogawa Richard · CIK 0001568078 · Director · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,750,000

F1 · kind: Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · price: Per the terms of an Agreement and Plan of Merger , dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Ogawa, as a shareholder of Pre-Merger Palomino, received 1,500,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Ogawa converted his SAFEs into 125,000 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

SEC source: 0001493152-25-019755 · ownership.xml · derivative · entry 2

Shealy Jeffrey B. · CIK 0001700683 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,666,666

Underlying: Common Stock · 833,333 shares

Expires not disclosed

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · derivative.expiration_date: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

SEC source: 0001493152-25-019755 · ownership.xml · nonDerivative · entry 1

Shealy Jeffrey B. · CIK 0001700683 · Director · President and CEO · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,666,666

F1 · kind: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).

F1 · price: Per the terms of an Agreement and Plan of Merger, dated September 29, 2025, Palomino Acquisition Co., a subsidiary of Issuer, merged into Rhino Subsidiary Inc. (f/k/a Palomino Laboratories Inc., "Pre-Merger Palomino"). Mr. Shealy, as a shareholder of Pre-Merger Palomino, received 3,000,000 shares of common stock, par value $0.0001 per share, of Issuer ("Common Stock") in exchange for his Pre-Merger Palomino shares. On September 29, 2025, Issuer closed a private placement offering and, in connection therewith, Mr. Shealy converted his SAFEs into 833,333 Units in the offering at a price of $1.20 per Unit. Each Unit consists of one share of the Common Stock and one warrant to purchase one share of Common Stock at an exercise price of $1.50. The warrants expire on the first anniversary of the date the Common Stock is admitted for trading or listed on an Approved Market (as defined in the warrant agreement).